Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VYGR

VYGR - Voyager Therapeutics Inc Stock Price, Fair Value and News

$3.96+0.02 (+0.51%)
Market Closed

54/100

VYGR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

VYGR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.48

Target 3M

$4.11

Target 6M

$4.23

VYGR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VYGR Price Action

Last 7 days

5.0%

Last 30 days

-2.0%

Last 90 days

-12.4%

Trailing 12 Months

-29.3%

VYGR RSI Chart

VYGR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VYGR Valuation

Market Cap

220.2M

Price/Earnings (Trailing)

-1.74

Price/Sales (Trailing)

7.03

EV/EBITDA

-1.43

Price/Free Cashflow

-1.85

VYGR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.48

Target 3M

$4.11

Target 6M

$4.23

VYGR Fundamentals

VYGR Revenue

Revenue (TTM)

31.3M

Rev. Growth (Yr)

-45.73%

Rev. Growth (Qtr)

157.02%

VYGR Earnings

Earnings (TTM)

-126.8M

Earnings Growth (Yr)

-208.4%

Earnings Growth (Qtr)

16.45%

VYGR Profitability

EBT Margin

-402.55%

Return on Equity

-57.67%

Return on Assets

-43.97%

Free Cashflow Yield

-53.98%

VYGR Investor Care

Shares Dilution (1Y)

1.78%

Diluted EPS (TTM)

-2.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202567.0M42.6M31.3M0
2024119.0M143.8M163.8M80.0M
202393.2M145.5M197.7M250.0M
202238.3M39.2M40.0M40.9M
2021159.6M132.2M15.9M37.4M
2020117.3M99.9M197.3M171.1M
201911.9M55.4M73.7M104.4M
20189.6M11.0M12.0M7.6M
201710.9M8.3M6.2M10.1M
201619.6M18.4M16.8M14.2M
201500017.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Voyager Therapeutics Inc

VYGR
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEvoyagertherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES125

Voyager Therapeutics Inc Frequently Asked Questions

VYGR is the stock ticker symbol of Voyager Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Voyager Therapeutics Inc is 220.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VYGR's fair value in chart for subscribers.

The fair value guage provides a quick view whether VYGR is over valued or under valued. Whether Voyager Therapeutics Inc is cheap or expensive depends on the assumptions which impact Voyager Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYGR.

As of Wed Jan 28 2026, VYGR's PE ratio (Price to Earnings) is -1.74 and Price to Sales (PS) ratio is 7.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYGR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Voyager Therapeutics Inc has provided -0.094 (multiply by 100 for percentage) rate of return.